Group 1 - The company held its fourth board meeting of the ninth session on September 22, 2025, with a total of 8 directors, including 5 present in person and 3 attending via communication [1][2] - The board elected Yu Guoquan as the representative director to execute company affairs, with his term lasting until the end of the ninth board session [2][3] - The board confirmed the members and convener of the audit committee, which consists of three directors, including a majority of independent directors, with Shizhu serving as the convener [4][5] Group 2 - The company signed a supplementary agreement to the fundraising four-party supervision agreement, which was originally established on January 10, 2022 [7][8] - The supplementary agreement modifies the use of the fundraising special account to include new projects, specifically the "annual production of 1000 tons of pyraclostrobin raw materials" and "annual production of 4200 tons of pyrethroid series products" [8] - The supplementary agreement is an integral part of the original fundraising supervision agreement and will take effect upon signing by all parties [9][10]